MSN Labs launches patented diabetes pill Jardiance after DRL, heats up potential legal battle
Earlier, ET reported that Dr Reddy's Labs has launched copies of Jardiance. It has a valid patent in India until 2025. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2021 Category: Pharmaceuticals Source Type: news

Empagliflozin's HFpEF Efficacy Catalyzes Redefinition of HF Empagliflozin's HFpEF Efficacy Catalyzes Redefinition of HF
Groundbreaking results from the EMPEROR-Preserved trial have helped catalyze a paradigm shift in how thought leaders view ejection fraction in making important distinctions among HF patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

Empagliflozin Benefits Tied to Drop in NT-proBNP Levels in Patients With Heart Failure Empagliflozin Benefits Tied to Drop in NT-proBNP Levels in Patients With Heart Failure
Empagliflozin reduced the risk of adverse cardiovascular and renal outcomes in heart failure patients regardless of baseline NT-proBNP levels, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)Breakthrough Designation awarded following empagliflozin ’s results in first and only successful trial for HFpEF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news

Empagliflozin Win in EMPEROR-Preserved HF, but Renal Outcomes Puzzle Empagliflozin Win in EMPEROR-Preserved HF, but Renal Outcomes Puzzle
The EMPEROR-Preserved trial of empagliflozin to treat patients with HFpEF comes with a lot more outcome analyses that also deserve attention, most notably some puzzling renal findings.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 1, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context
Javed Butler discusses the details of the trial on empagliflozin in HFpEF with Ileana Pi ña and what might be learned from the subgroup analyses.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 31, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Incremental, Not Monumental, Win for Empagliflozin in HFpEF Incremental, Not Monumental, Win for Empagliflozin in HFpEF
The modest effects compel clinicians to be selective in the use of this costly drug, but there will be subgroups of patients who may benefit more, says John Mandrola, MD.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2021 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news

EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection fraction, a practice-changing result.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 27, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

emperor-preserved-heart-failure-full-data
Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction  In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21  percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure1The benefit in the primary endpoint was independent of ejection fraction or diabetes status1Empagliflozin also reduced the relative risk of first and recurrent hospitalizations for h...
Source: Boehringer Ingelheim Corporate News - August 27, 2021 Category: Research Source Type: news

FDA Okays Empagliflozin for HFrEF FDA Okays Empagliflozin for HFrEF
The drug is approved as a treatment for adults with heart failure with reduced ejection fraction (HFrEF) regardless of whether patients have diabetes.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 19, 2021 Category: Cardiology Tags: Cardiology News Alert Source Type: news

FDA Approves Jardiance (empagliflozin) to Treat Adults Living with Heart Failure with Reduced Ejection Fraction
Ridgefield, Conn. and Indianapolis, August 18, 2021– Jardiance (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 18, 2021 Category: Drugs & Pharmacology Source Type: news

EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF
The SGLT2 inhibitor met the primary endpoint in adults with heart failure and preserved ejection fraction, with full results to be presented at ESC 2021.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

emperor-preserved-heart-failure-toplineresults
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction  The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF)HFpEF has been classified as “the single largest unmet need in cardiovascular medicine”1 based on prevalence, poor outcomes and the absence of clinically proven therapies to date2W...
Source: Boehringer Ingelheim Corporate News - July 6, 2021 Category: Research Source Type: news

Synjardy XR (empagliflozin and metformin extended-release)
Title: Synjardy XR (empagliflozin and metformin extended-release)Category: MedicationsCreated: 7/2/2021 12:00:00 AMLast Editorial Review: 7/2/2021 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - July 2, 2021 Category: Endocrinology Source Type: news

Synjardy (empagliflozin and metformin)
Title: Synjardy (empagliflozin and metformin)Category: MedicationsCreated: 6/30/2021 12:00:00 AMLast Editorial Review: 6/30/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 30, 2021 Category: Drugs & Pharmacology Source Type: news

Glyxambi (empagliflozin and linagliptin)
Title: Glyxambi (empagliflozin and linagliptin)Category: MedicationsCreated: 6/29/2021 12:00:00 AMLast Editorial Review: 6/29/2021 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - June 29, 2021 Category: Endocrinology Source Type: news

real-world-benefit-shown-in-T2D-treatment
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes  Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitorsThis analysis, which includes European data pooled with data from Israel and East Asia, was presented for the first time at the American Diabetes Association Scientific Sessions, 25 June 20211  EMPRISE data complemen...
Source: Boehringer Ingelheim Corporate News - June 28, 2021 Category: Research Source Type: news

reduced-heart-failure-treatment-approval-europe
Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fractionThis new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for heart failure with reduced ejection fraction in adults with or without diabetes and an eGFR of ≥20ml/min/1.73 m2Heart failure is the leading cause of hospitalization in Europe,   with prevalence expected to increase as the population agesJardiance was first approved in May 2014 for the treatment of adults ...
Source: Boehringer Ingelheim Corporate News - June 21, 2021 Category: Research Source Type: news

Pill for diabetics could also protect against heart failure
The medication, empagliflozin, is thought to stimulate the heart, making it more efficient and leading to 'significant improvements' in function after just three months. (Source: the Mail online | Health)
Source: the Mail online | Health - June 12, 2021 Category: Consumer Health News Source Type: news

emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for Jardiance ® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fractionThe positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk of cardiovascular death or hospitalization for heart failure  The results were observed in adults with heart failure with reduced ejection fraction (HFrEF), with or without diabetesJardiance is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 21, 2021 Category: Research Source Type: news

Empagliflozin cost effective in patients with T2DM and CVD
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news

Empagliflozin least costly option for preventing heart failure in T2DM patients?
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Cardiac and Kidney Benefits of Empagliflozin in Heart Failure
This study examined the effect of empagliflozin on cardiovascular and kidney outcomes in heart failure patients with or without chronic kidney disease.Circulation (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 30, 2021 Category: Transplant Surgery Tags: Cardiology Journal Article Source Type: news

PHARMAC approves funding for empagliflozin and dulaglutide
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2021 Category: Drugs & Pharmacology Source Type: news

Jardiance ® associated with a total cost of care savings of more...
Highmark and Boehringer Ingelheim announced positive results from their outcomes-based agreement, which showed that adults with type 2 diabetes and known cardiovascular disease who took...(PRWeb December 15, 2020)Read the full story at https://www.prweb.com/releases/jardiance_associated_with_a_total_cost_of_care_savings_of_more_than_20_according_to_results_from_an_outcomes_based_agreement_between_boehringer_ingelheim_and_highmark/prweb17613452.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 15, 2020 Category: Pharmaceuticals Source Type: news

empa-reg-outcome-recurrent-events
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME ® trialIn new results published in The Lancet Diabetes& Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular diseaseRecurrent cardiovascular events in people with type 2 diabetes are responsible for considerable clinical and s...
Source: Boehringer Ingelheim Corporate News - November 18, 2020 Category: Research Source Type: news

Empagliflozin Favorably Reshaped LVs in HFrEF Patients Empagliflozin Favorably Reshaped LVs in HFrEF Patients
Treatment with the SGLT2 inhibitor empagliflozin led to significant reductions in both left ventricular end systolic and diastolic volumes in two independent randomized studies of patients with heart failure with reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

October 9 2020 This Week in Cardiology October 9 2020 This Week in Cardiology
COVID-19, scientific philosophy, left main coronary artery disease, empagliflozin and the SGLT2 inhibitors are the topics discussed by John Mandrola, MD in this week ’ s podcasttheheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 9, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Empagliflozin's HFrEF Benefit Steady With Sacubitril/Valsartan Empagliflozin's HFrEF Benefit Steady With Sacubitril/Valsartan
The SGLT2 inhibitor empagliflozin works just as well when added on top of a second major agent used to treat patients with heart failure and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 7, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Empagliflozin Superior to Placebo for Heart Failure
WEDNESDAY, Sept. 2, 2020 -- Among patients with heart failure, risk for cardiovascular death or hospitalization with heart failure is lower for those receiving empagliflozin compared with placebo, according to a study published online Aug. 29 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 2, 2020 Category: Pharmaceuticals Source Type: news

SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context
Dr Ileana Pi ñ a asks the lead investigator how his trial on empagliflozin in HFrEF compares with DAPA-HF. They speculate on the likely mechanism of action of these relatively new drugs.theheart.org on Medscape (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 1, 2020 Category: Intensive Care Tags: Cardiology Commentary Source Type: news

Empagliflozin's HFrEF Benefit Solidifies Class Effects Empagliflozin's HFrEF Benefit Solidifies Class Effects
The 25% cut in primary endpoints among patients with HFrEF receiving empagliflozin in EMPEROR-Reduced matched the benefit seen before from dapagliflozin in DAPA-HF.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Positive Top-line Results for Another SGLT2 Inhibitor in HF Positive Top-line Results for Another SGLT2 Inhibitor in HF
Empagliflozin reduced the risk of CV death or heart failure hospitalization in a phase 3 trial of adults with HF and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 31, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Jardiance(R) meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
Jardiance (empagliflozin) significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction ... Biopharmaceuticals, Endocrinology Eli Lilly, Jardiance, empagliflozin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 30, 2020 Category: Pharmaceuticals Source Type: news

emperor-reduced-heart-failure-toplineresults
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetesEmpagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction  Treatment of heart failure is an important unmet need with over half of those diagnosed dying within five years1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 30, 2020 Category: Research Source Type: news

Empagliflozin 2nd-line therapy in T2DM: better outcomes, lower cost in US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2020 Category: Drugs & Pharmacology Source Type: news

EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes
The SGLT2 inhibitor reduced the need to start insulin treatment or intensify existing insulin treatment compared with placebo in a post-hoc analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

DCRI-collaboration-empact-mi
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin ’s effects following an acute myocardial infarction Ischemic heart disease, including myocardial infarction, is the leading cause of death in the world1EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetesThe trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the li...
Source: Boehringer Ingelheim Corporate News - May 26, 2020 Category: Research Source Type: news

Fda-crl-t1d
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2020 Category: Research Source Type: news

FDA-Fast-Track-chronic-kidney-disease
U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 12, 2020 Category: Research Source Type: news

Trijardy XR (Empagliflozin, Linagliptin, and Metformin Hydrochloride Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2020 Category: Drugs & Pharmacology Source Type: news

Trijardy XR (Empagliflozin, Linagliptin, and Metformin Hydrochloride Extended-release Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 5, 2020 Category: Drugs & Pharmacology Source Type: news

Monthly News Roundup - January 2020
Trijardy XR: A Triple Drug Combo Approved for Type 2 Diabetes In January, the US Food and Drug Administration (FDA) approved once-daily Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended release tablets) to lower blood... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2020 Category: Pharmaceuticals Source Type: news

FDA OKs New Triple-Combo Pill, Trijardy XR, for Type 2 Diabetes FDA OKs New Triple-Combo Pill, Trijardy XR, for Type 2 Diabetes
The once-daily treatment comprises empagliflozin (Jardiance), linagliptin (Tradjenta), and extended-release metformin hydrochloride. It will be available in four different dosages.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 28, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults
RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 27, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 27, 2020 Category: Drugs & Pharmacology Source Type: news

Lilly, Boehringer's Jardiance has heart failure trial setback
Boehringer Ingelheim and Eli Lilly announced failing results in two trials evaluating Jardiance in adults with chronic heart failure. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 13, 2019 Category: Pharmaceuticals Source Type: news

EMPERIAL-heart-failure-toplineresults
Boehringer Ingelheim and Lilly provide update on empagliflozin phase III exercise ability studies in chronic heart failure (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2019 Category: Research Source Type: news

EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonistsThis analysis on effectiveness also shows empagliflozin was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists1  A second analysis on healthcare resource utilisation shows empagliflozin was associated with a reduced risk in all-cause hospitalisations compared with DPP-4 inhibitors2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 17, 2019 Category: Research Source Type: news

FDA Panel Rejects Empagliflozin for Use in Type 1 Diabetes FDA Panel Rejects Empagliflozin for Use in Type 1 Diabetes
The FDA advisers said the pivotal approval study was too short and did not involve enough patients to characterize efficacy or safety.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 14, 2019 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news

Empulse
Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilisedEMPULSE is a superiority study that will assess the clinical benefit, safety and tolerability of 10 mg daily empagliflozin in acute heart failure1  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 12, 2019 Category: Research Source Type: news